vs
Side-by-side financial comparison of COLONY BANKCORP INC (CBAN) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
COLONY BANKCORP INC is the larger business by last-quarter revenue ($39.9M vs $28.1M, roughly 1.4× ARS Pharmaceuticals, Inc.). COLONY BANKCORP INC runs the higher net margin — 20.6% vs -147.1%, a 167.7% gap on every dollar of revenue.
Colony Bankcorp Inc is a US-based bank holding company that operates Colony Bank. It provides a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving retail customers and small-to-medium enterprises across the state of Georgia.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
CBAN vs SPRY — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $28.1M |
| Net Profit | $8.2M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | — | -147.6% |
| Net Margin | 20.6% | -147.1% |
| Revenue YoY | — | -67.6% |
| Net Profit YoY | 24.1% | -182.8% |
| EPS (diluted) | — | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $39.9M | — | ||
| Q4 25 | $36.9M | $28.1M | ||
| Q3 25 | $32.8M | $32.5M | ||
| Q2 25 | $32.5M | $15.7M | ||
| Q1 25 | $30.0M | $8.0M | ||
| Q4 24 | $30.8M | $86.6M | ||
| Q3 24 | $28.6M | $2.1M | ||
| Q2 24 | $27.9M | $500.0K |
| Q1 26 | $8.2M | — | ||
| Q4 25 | — | $-41.3M | ||
| Q3 25 | $5.8M | $-51.2M | ||
| Q2 25 | $8.0M | $-44.9M | ||
| Q1 25 | $6.6M | $-33.9M | ||
| Q4 24 | — | $49.9M | ||
| Q3 24 | $5.6M | $-19.1M | ||
| Q2 24 | $5.5M | $-12.5M |
| Q1 26 | — | — | ||
| Q4 25 | 25.9% | -147.6% | ||
| Q3 25 | 22.2% | -163.7% | ||
| Q2 25 | 30.9% | -302.9% | ||
| Q1 25 | 27.6% | -466.3% | ||
| Q4 24 | 28.8% | 54.5% | ||
| Q3 24 | 24.6% | -1051.6% | ||
| Q2 24 | 24.8% | -3068.0% |
| Q1 26 | 20.6% | — | ||
| Q4 25 | — | -147.1% | ||
| Q3 25 | 17.7% | -157.4% | ||
| Q2 25 | 24.6% | -285.6% | ||
| Q1 25 | 22.0% | -425.7% | ||
| Q4 24 | — | 57.7% | ||
| Q3 24 | 19.7% | -925.0% | ||
| Q2 24 | 19.6% | -2503.2% |
| Q1 26 | — | — | ||
| Q4 25 | $0.42 | $-0.41 | ||
| Q3 25 | $0.33 | $-0.52 | ||
| Q2 25 | $0.46 | $-0.46 | ||
| Q1 25 | $0.38 | $-0.35 | ||
| Q4 24 | $0.43 | $0.52 | ||
| Q3 24 | $0.32 | $-0.20 | ||
| Q2 24 | $0.31 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $295.8M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $380.4M | $114.3M |
| Total Assets | $3.7B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $295.8M | — | ||
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M |
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $248.0M | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $380.4M | — | ||
| Q4 25 | $375.9M | $114.3M | ||
| Q3 25 | $302.3M | $147.7M | ||
| Q2 25 | $293.9M | $192.3M | ||
| Q1 25 | $286.9M | $229.0M | ||
| Q4 24 | $278.7M | $256.8M | ||
| Q3 24 | $276.1M | $201.0M | ||
| Q2 24 | $264.7M | $215.2M |
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.7B | $327.7M | ||
| Q3 25 | $3.2B | $372.8M | ||
| Q2 25 | $3.1B | $313.5M | ||
| Q1 25 | $3.2B | $327.3M | ||
| Q4 24 | $3.1B | $351.2M | ||
| Q3 24 | $3.1B | $217.6M | ||
| Q2 24 | $3.0B | $222.0M |
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.89× | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-43.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-5.5M | $-43.5M | ||
| Q3 25 | $14.4M | $-47.0M | ||
| Q2 25 | $15.8M | $-39.6M | ||
| Q1 25 | $17.9M | $-40.7M | ||
| Q4 24 | $23.4M | $42.0M | ||
| Q3 24 | $20.5M | $-14.5M | ||
| Q2 24 | $1.1M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-6.9M | — | ||
| Q3 25 | $14.1M | $-47.2M | ||
| Q2 25 | $15.8M | $-39.6M | ||
| Q1 25 | $17.6M | $-40.8M | ||
| Q4 24 | $22.3M | $41.7M | ||
| Q3 24 | $20.2M | $-14.6M | ||
| Q2 24 | $990.0K | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | -18.7% | — | ||
| Q3 25 | 42.9% | -145.4% | ||
| Q2 25 | 48.5% | -252.2% | ||
| Q1 25 | 58.7% | -512.1% | ||
| Q4 24 | 72.5% | 48.2% | ||
| Q3 24 | 70.6% | -706.3% | ||
| Q2 24 | 3.5% | -1463.4% |
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | 0.0% | ||
| Q3 25 | 1.1% | 0.6% | ||
| Q2 25 | 0.3% | 0.3% | ||
| Q1 25 | 1.2% | 1.1% | ||
| Q4 24 | 3.5% | 0.3% | ||
| Q3 24 | 1.0% | 6.8% | ||
| Q2 24 | 0.5% | 7.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.48× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 2.71× | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | 3.64× | — | ||
| Q2 24 | 0.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
